Combination of the natural product capsaicin and docetaxel synergistically kills human prostate cancer cells through the metabolic regulator AMP-activated kinase
Open Access
- 8 March 2019
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 54
Abstract
Current chemotherapy for castration-resistant prostate cancer is established on taxane-based compounds like docetaxel. However, eventually, the development of toxic side effects and resistance limits the therapeutic benefit being the major concern in the treatment of prostate cancer. Combination therapies in many cases, enhance drug efficacy and delay the appearance of undesired effects, representing an important option for the treatment of castration-resistant prostate cancer. In this study, we tested the efficacy of the combination of docetaxel and capsaicin, the pungent ingredient of hot chili peppers, on prostate cancer cells proliferation. Prostate cancer LNCaP and PC3 cell lines were used in this study. Levels of total and phosphorylated forms of Akt, mTOR, S6, LKB1, AMPK and ACC were determined by Western blot. AMPK, LKB1 and Akt knock down was performed by siRNA. PTEN was overexpressed by transient transfection with plasmids. Xenograft prostate tumors were induced in nude mice and treatments (docetaxel and capsaicin) were administered intraperitoneally. Statistical analyses were performed with GraphPad software. Combination index was calculated with Compusyn software. Docetaxel and capsaicin synergistically inhibited the growth of LNCaP and PC3 cells, with a combination index lower than 1 for most of the combinations tested. Co-treatment with docetaxel and capsaicin notably decreased Akt and its downstream targets mTOR and S6 phosphorylation. Overexpression of PTEN phosphatase abrogated the synergistic antiproliferative effect of docetaxel and capsaicin. The combined treatment also increased the phosphorylation of AMP-activated kinase (AMPK) and the phosphorylation of its substrate ACC. In addition, pharmacological inhibition of AMPK with dorsomorphin (compound C) as well as knock down by siRNA of AMPK or its upstream kinase LKB1, abolished the synergy of docetaxel and capsaicin. Mechanistically, we showed that the synergistic anti-proliferative effect may be attributed to two independent effects: Inhibition of the PI3K/Akt/mTOR signaling pathway by one side, and AMPK activation by the other. In vivo experiments confirmed the synergistic effects of docetaxel and capsaicin in reducing the tumor growth of PC3 cells. Combination of docetaxel and capsaicin represents a therapeutically relevant approach for the treatment of Prostate Cancer.Keywords
Funding Information
- Fundación Tatiana Pérez de Guzmán el Bueno (Patrocinio 2013-01, 2019-001)
This publication has 34 references indexed in Scilit:
- Nanoways to overcome docetaxel resistance in prostate cancerDrug Resistance Updates, 2014
- Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate CancerJournal of Urology, 2014
- How to calculate sample size in animal studies?Journal of Pharmacology and Pharmacotherapeutics, 2013
- Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyOncogene, 2013
- Cross-Talk between AMPK and mTOR in Regulating Energy BalanceCritical Reviews in Food Science and Nutrition, 2012
- Geraniol induces cooperative interaction of apoptosis and autophagy to elicit cell death in PC-3 prostate cancer cellsInternational Journal of Oncology, 2011
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay MethodCancer Research, 2010
- Additivity Versus Synergy: A Theoretical Analysis of Implications for Anesthetic MechanismsAnesthesia & Analgesia, 2008
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- The AMP-activated protein kinase pathway – new players upstream and downstreamJournal of Cell Science, 2004